Healthcare Innovations II, 6
Back to All Primary TrustsPortfolio Holdings by Security (As of Deposit Date)
| Ticker | Security Description | Deposit % |
|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 3.33 |
| ARCT | Arcturus Therapeutics Holdings, Inc. | 3.32 |
| ARDX | Ardelyx, Inc. | 3.34 |
| CMPS | Compass Pathways | 3.34 |
| CRMD | CORMEDIX INC. | 3.32 |
| DAWN | DAY ONE BIOPHARMACEUTICALS, INC. | 3.34 |
| FLGT | FULGENT GENETICS INC | 3.35 |
| GOSS | Gossamer Bio Inc | 3.36 |
| GRFS | Grifols, S.A. | 3.37 |
| IMVT | Immunovant Inc | 3.40 |
| INDV | Indivior PLC | 3.40 |
| JAZZ | Jazz Pharmaceuticals Plc | 3.29 |
| KALV | KalVista Pharmaceuticals, Inc. | 3.32 |
| KURA | Kura Oncology, Inc. | 3.25 |
| MGTX | Meiragtx Holdings Plc | 3.31 |
| OCGN | Ocugen Inc | 3.3 |
| OLMA | Olema Pharmaceuticals, Inc. | 3.28 |
| PCRX | Pacira Pharmaceuticals, Inc. | 3.39 |
| PHAT | PHATHOM PHARMACEUTICALS, INC. | 3.36 |
| PROK | ProKidney Corp | 3.36 |
| RIGL | Rigel Pharmaceuticals, Inc. | 3.35 |
| SNDX | Syndax Pharmaceuticals Inc | 3.27 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 3.35 |
| TSHA | Taysha Gene Therapies, Inc. | 3.32 |
| TVTX | Retrophin, Inc. | 3.28 |
| URGN | Urogen Pharma Ltd | 3.33 |
| VRDN | Viridian Therapeutics Inc | 3.37 |
| VSTM | Verastem, Inc. | 3.33 |
| ZLAB | Zai Lab Ltd. | 3.33 |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 3.34 |
Health Care
| Ticker | Security Description | Deposit % |
|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 3.33 |
| ARCT | Arcturus Therapeutics Holdings, Inc. | 3.32 |
| ARDX | Ardelyx, Inc. | 3.34 |
| CMPS | Compass Pathways | 3.34 |
| CRMD | CORMEDIX INC. | 3.32 |
| DAWN | DAY ONE BIOPHARMACEUTICALS, INC. | 3.34 |
| FLGT | FULGENT GENETICS INC | 3.35 |
| GOSS | Gossamer Bio Inc | 3.36 |
| GRFS | Grifols, S.A. | 3.37 |
| IMVT | Immunovant Inc | 3.40 |
| INDV | Indivior PLC | 3.40 |
| JAZZ | Jazz Pharmaceuticals Plc | 3.29 |
| KALV | KalVista Pharmaceuticals, Inc. | 3.32 |
| KURA | Kura Oncology, Inc. | 3.25 |
| MGTX | Meiragtx Holdings Plc | 3.31 |
| OCGN | Ocugen Inc | 3.3 |
| OLMA | Olema Pharmaceuticals, Inc. | 3.28 |
| PCRX | Pacira Pharmaceuticals, Inc. | 3.39 |
| PHAT | PHATHOM PHARMACEUTICALS, INC. | 3.36 |
| PROK | ProKidney Corp | 3.36 |
| RIGL | Rigel Pharmaceuticals, Inc. | 3.35 |
| SNDX | Syndax Pharmaceuticals Inc | 3.27 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 3.35 |
| TSHA | Taysha Gene Therapies, Inc. | 3.32 |
| TVTX | Retrophin, Inc. | 3.28 |
| URGN | Urogen Pharma Ltd | 3.33 |
| VRDN | Viridian Therapeutics Inc | 3.37 |
| VSTM | Verastem, Inc. | 3.33 |
| ZLAB | Zai Lab Ltd. | 3.33 |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 3.34 |
Summary
Description
-
Trust Name Healthcare Innovations II, 6
-
Trust Symbol STHCFX
Deposit Data
-
Deposit Date 10/29/2025
-
Termination Date 10/28/2027
-
Minimum Investment 100
-
Distribution Frequency Monthly (if any)
-
Initial Public Offer Price $10.00
-
Historical 12-Month Dist.* 0.000
CUSIP
-
Cash Cusip 83208C109
-
Reinvest Cusip 83208C117
-
Fee Cash Cusip 83208C125
-
Fee Invest Cusip 83208C133
Documents
*The Historical 12-Month Distribution of Trust Holdings is as of 07/01/2025. If the Trust deposited after, or 90 days prior to, 07/01/2025, the distribution is as of deposit date. The Historical 12-Month Distribution is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust’s portfolio over the 12 months preceding the trust’s date of deposit reduced to account for the effects of trust fees and expenses. This historical distribution is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust. The distributions paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future.